Key result
GPX-150 treatment in metastatic and unresectable soft tissue sarcoma resulted in progression-free survival rates of 38% at 6 months and 12% at 12 months, with no evidence of chronic cardiotoxicity.
Why the study?
GPX-150 was developed to reduce doxorubicin-related cardiotoxicity, prompting further evaluation of its efficacy, safety, and cardiac effects, specifically LVEF, in metastatic and unresectable soft tissue sarcoma.
Does GPX-150 provide efficacy without irreversible, cumulative dose-dependent chronic cardiotoxicity in patients with metastatic and unresectable soft tissue sarcoma?
Does GPX-150 provide efficacy without irreversible, cumulative dose-dependent chronic cardiotoxicity in patients with metastatic and unresectable soft tissue sarcoma?
GPX-150 demonstrated efficacy in soft tissue sarcoma without causing irreversible, cumulative dose-dependent chronic cardiotoxicity, potentially offering a safer alternative to doxorubicin.
No takes yet. Share an insight, caveat, or question.
GPX-150 may support cardiotoxicity-sparing treatment in metastatic soft tissue sarcoma; leaves open need for randomized confirmation of efficacy.
Tine et al. (2019) studied Metastatic and unresectable soft tissue sarcoma. 13-Deoxy, 5-iminodoxorubicin (GPX-150) was evaluated on Progression-free survival (PFS) at 6 months. GPX-150 treatment in metastatic and unresectable soft tissue sarcoma resulted in progression-free survival rates of 38% at 6 months and 12% at 12 months, with no evidence of chronic cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: